CL2020003392A1 - Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172) - Google Patents

Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)

Info

Publication number
CL2020003392A1
CL2020003392A1 CL2020003392A CL2020003392A CL2020003392A1 CL 2020003392 A1 CL2020003392 A1 CL 2020003392A1 CL 2020003392 A CL2020003392 A CL 2020003392A CL 2020003392 A CL2020003392 A CL 2020003392A CL 2020003392 A1 CL2020003392 A1 CL 2020003392A1
Authority
CL
Chile
Prior art keywords
extracellular domain
cancer treatment
divisional application
domain polypeptides
ecd
Prior art date
Application number
CL2020003392A
Other languages
English (en)
Inventor
Thomas Brennan
David Bellovin
David Busha
Barbara Sennino
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of CL2020003392A1 publication Critical patent/CL2020003392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud hace referencia a polipéptidos del dominio extracelular (ECD) de la CD80 (B7- 1) y moléculas de fusión al ECD de la CD80 y su uso en el tratamiento del cáncer, tanto solos como en combinación con otros agentes terapéuticos, tales como agentes que estimulan el sistema inmunitario tales como inhibidores de PD-1/PD-L1. También se refiere a un método de mejora de la eficacia de una proteína de fusión.
CL2020003392A 2015-11-02 2020-12-28 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172) CL2020003392A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562249836P 2015-11-02 2015-11-02
US201662373654P 2016-08-11 2016-08-11

Publications (1)

Publication Number Publication Date
CL2020003392A1 true CL2020003392A1 (es) 2021-07-19

Family

ID=57286882

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018001172A CL2018001172A1 (es) 2015-11-02 2018-05-02 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
CL2020003392A CL2020003392A1 (es) 2015-11-02 2020-12-28 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001172A CL2018001172A1 (es) 2015-11-02 2018-05-02 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer

Country Status (22)

Country Link
US (4) US10273281B2 (es)
EP (1) EP3371208B8 (es)
JP (1) JP6936221B2 (es)
KR (1) KR20180069903A (es)
CN (1) CN108884139A (es)
AU (1) AU2016350701B2 (es)
BR (1) BR112018008865A8 (es)
CA (1) CA3001131A1 (es)
CL (2) CL2018001172A1 (es)
CO (1) CO2018004132A2 (es)
CR (1) CR20180306A (es)
EA (1) EA201891106A1 (es)
EC (1) ECSP18041501A (es)
ES (1) ES2994930T3 (es)
IL (1) IL258725A (es)
MA (1) MA43163A (es)
MX (1) MX2018005517A (es)
PE (1) PE20181300A1 (es)
PH (1) PH12018500933A1 (es)
SG (1) SG11201803009VA (es)
TW (1) TW201722985A (es)
WO (1) WO2017079117A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
CN110662758A (zh) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CA3057866A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
BR112020003533A2 (pt) 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
WO2020047087A1 (en) * 2018-08-29 2020-03-05 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
CA3086486A1 (en) 2018-09-17 2020-03-26 Gi Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein, and use thereof
KR20210089146A (ko) * 2018-09-19 2021-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
US20220031806A1 (en) * 2019-02-22 2022-02-03 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
EP3956362A1 (en) 2019-04-18 2022-02-23 Five Prime Therapeutics, Inc. Bioassay for t-cell co-stimulatory proteins containing fc domains
US11788072B2 (en) * 2019-04-30 2023-10-17 Innovative Cellular Therapeutics Holdings, Ltd. Activation of APC in immunotherapy
WO2020227062A1 (en) 2019-05-03 2020-11-12 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins
IL292934A (en) 2019-11-20 2022-07-01 Gi Cell Inc Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium
KR102351020B1 (ko) * 2019-11-20 2022-01-14 주식회사 지아이셀 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법
EP4063490A4 (en) 2019-11-20 2023-08-23 GI Cell, Inc. COMPOSITION FOR THE CULTURE OF REGULATORY T LYMPHOCYTES AND THEIR USE
CN110732021B (zh) * 2019-11-21 2020-08-25 北京启辰生生物科技有限公司 用于解除肿瘤免疫抑制的组合物及其应用
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用
MX2022006426A (es) * 2019-11-27 2022-06-22 Gi Innovation Inc Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80.
JP7488337B2 (ja) * 2019-11-27 2024-05-21 ジーアイ・セル・インコーポレイテッド Ｉｌ－２タンパク質及びｃｄ８０タンパク質を含む融合タンパク質及びｎｋ細胞を含む抗癌治療用組成物
EP4110802A1 (en) * 2020-02-26 2023-01-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
JP7565384B2 (ja) 2020-06-03 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＣＤ８０細胞外ドメインＦｃ融合タンパク質をコードするリコンビナントラブドウイルス
KR102373965B1 (ko) 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
WO2022226170A1 (en) * 2021-04-22 2022-10-27 Cornell University The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr
WO2025167357A1 (zh) * 2024-02-06 2025-08-14 启愈生物技术(上海)有限公司 Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
WO1995024217A1 (en) 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6491925B2 (en) 1996-08-15 2002-12-10 Emory University Compositions and methods for cancer prophylaxis and/or treatment
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US7011833B1 (en) 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US7064111B1 (en) 1999-10-05 2006-06-20 Georgetown University Use of soluble costimulatory factor for tumor immuno-gene therapy
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
WO2003039486A2 (en) 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
CN1826324B (zh) 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
AU2004264901B2 (en) 2003-08-04 2009-12-10 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
ES2564127T5 (es) 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1812601A2 (en) 2004-10-22 2007-08-01 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US7635570B2 (en) 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
RS52711B (sr) 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
EP1913157B2 (en) 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP2009505658A (ja) 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2013348A4 (en) 2006-03-30 2009-09-02 Univ California METHOD AND COMPOSITIONS FOR LOCALIZED SECRETION OF ANTI-CTLA-4 ANTIBODIES
WO2008033442A2 (en) 2006-09-12 2008-03-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008037080A1 (en) 2006-09-29 2008-04-03 Universite De Montreal Methods and compositions for immune response modulation and uses thereof
PE20090690A1 (es) 2007-03-13 2009-06-22 Amgen Inc Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr
CA2682266A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Treatment of hodgkins lymphoma
CN101679522A (zh) 2007-03-28 2010-03-24 拜奥根Idec公司 肿瘤微环境的调控
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
CN101358225B (zh) * 2007-07-30 2012-02-01 厦门大学 高唾液酸含量的免疫球蛋白抗体的制备方法与应用
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101998965B (zh) * 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
US20100285039A1 (en) 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
EP2250279B1 (en) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1 antibodies with reduced fc ligand affinity
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
NO2694640T3 (es) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
CN107988156B (zh) 2011-06-30 2022-01-04 建新公司 T细胞活化的抑制剂
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014100139A1 (en) * 2012-12-18 2014-06-26 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
CA2904528C (en) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US20160024179A1 (en) 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US20170044268A1 (en) 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
EP3194440A1 (en) 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US10584157B2 (en) 2015-03-16 2020-03-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Isolated peptides derived from the B7 ligand dimer interface and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
AU2016323069A1 (en) 2015-09-14 2018-04-12 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
SG11201805255TA (en) 2015-12-23 2018-07-30 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
KR20180111870A (ko) 2016-02-25 2018-10-11 셀 메디카 스위처란트 아게 Pd-l1에 대한 결합 성분
US20190062400A1 (en) 2016-03-02 2019-02-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2019507180A (ja) 2016-03-04 2019-03-14 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ がんに対する組合せ療法
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
JP7421338B2 (ja) 2016-09-27 2024-01-24 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
EP3529361B1 (en) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CA3057866A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
WO2020047087A1 (en) 2018-08-29 2020-03-05 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
US20220031806A1 (en) 2019-02-22 2022-02-03 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
WO2020227062A1 (en) 2019-05-03 2020-11-12 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Also Published As

Publication number Publication date
MA43163A (fr) 2018-09-12
EA201891106A1 (ru) 2018-12-28
ES2994930T3 (en) 2025-02-04
JP2018535204A (ja) 2018-11-29
US12365719B2 (en) 2025-07-22
US10273281B2 (en) 2019-04-30
US11098103B2 (en) 2021-08-24
KR20180069903A (ko) 2018-06-25
CN108884139A (zh) 2018-11-23
PH12018500933A1 (en) 2018-11-19
US20170145071A1 (en) 2017-05-25
US20190202889A1 (en) 2019-07-04
US20240041979A1 (en) 2024-02-08
CR20180306A (es) 2018-10-16
TW201722985A (zh) 2017-07-01
JP6936221B2 (ja) 2021-09-15
EP3371208B1 (en) 2024-09-18
PE20181300A1 (es) 2018-08-09
ECSP18041501A (es) 2018-06-30
EP3371208A1 (en) 2018-09-12
EP3371208B8 (en) 2024-10-23
IL258725A (en) 2018-06-28
SG11201803009VA (en) 2018-05-30
US20190194288A1 (en) 2019-06-27
MX2018005517A (es) 2018-11-09
CL2018001172A1 (es) 2018-09-21
BR112018008865A2 (pt) 2018-11-06
CO2018004132A2 (es) 2018-11-30
CA3001131A1 (en) 2017-05-11
BR112018008865A8 (pt) 2019-02-26
AU2016350701B2 (en) 2021-08-19
WO2017079117A1 (en) 2017-05-11
AU2016350701A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
MX2018006181A (es) Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
PH12018502429A1 (en) Antibody molecules for cancer treatment
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MX2017003227A (es) Terapias de combinacion de inhibidores de alk.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2019012849A (es) Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.